Co-administration of resveratrol and beta-aminopropionitrile attenuates liver fibrosis development via targeting lysyl oxidase in CCl₄-induced liver fibrosis in rats

Abstract

Objectives: In the current study, we aimed to investigate the effect of administration of resveratrol (RES) and beta-aminopropionitrile (BAPN) separately and together on the liver fibrosis progression via regulation of the gene expression and protein level of lysyl oxidase (LOX).

Materials and methods: The six-week old Wistar rats received carbon tetrachloride (CCl₄) intraperitoneally and RES and BAPN were administrated orally for eight weeks. The hepatoprotective effects of RES, BAPN, and combination treatment were evaluated. Then the hepatic protein and gene expression levels of LOX were measured.

Results: Both RES and BAPN showed the antifibrotic effect through the reduction of collagen fiber bundles, hepatic hydroxyproline content, and protein level of LOX. The antifibrotic effect increased when RES and BAPN up-taken together.

Conclusion: The co-administration of RES and BAPN can be considered as a promising therapeutic approach via targeting LOX.

Keywords:

• Resveratrol
• beta-aminopropionitrile
• hepatic fibrosis
• carbon tetrachloride
• protein-lysine 6-oxidase

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This study was supported by Hamadan University of Medical Sciences [No: 9507274280].